Scarica l'app Stockscreener
74.89
0.91%
-0.8003
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Dexcom Inc Borsa (DXCM) Ultime notizie
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) executive plans 26,756-share stock sale - Stock Titan
Dexcom stock trades steady as diabetes CGM growth supports earnings outlook - Ad-hoc-news.de
Dexcom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MSN
Dexcom stock holds steady as investors weigh Q1 2026 growth - ad-hoc-news.de
Enterprise value to EBIT forward of DexCom, Inc. – FWB:DC4 - TradingView
DexCom (DXCM) Back In Focus As Canada Approval Tests Its Valuation - Sahm
Dexcom stock trades steady as diabetes technology growth supports valuation - ad-hoc-news.de
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom Inc. Stock Climbs 7.2%, Outperforms Market - webull.com
DXCM5813816 Bond Profile — Key Metrics - TradingView
Form 4 DexCom Inc For: 16 July By Investing.com - Investing.com Nigeria
Dexcom stock trades steady as CGM demand supports revenue growth - ad-hoc-news.de
Truist raises DexCom stock price target to $87 on growth outlook By Investing.com - Investing.com South Africa
Dexcom EVP chief legal compliance off sells $126,514 in stock By Investing.com - Investing.com South Africa
DEXCOM INC : TRUIST SECURITIES RAISES TARGET PRICE TO $87 FROM $80 - Bitget
ETFs Investing in DexCom, Inc. Stocks - TradingView
DexCom Inc (DXCM) Stock Up 7.2% and Still Undervalued -- GF Scor - GuruFocus
DexCom, Inc.’s stock price soars to $77.98, marking a remarkable 7.22% increase - Smartkarma
Dexcom EVP chief legal compliance off sells $126,514 in stock - Investing.com
DEXCOM INC (DXCM) EVP reports 1,700-share planned stock sale in Form 4 - Stock Titan
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Why DexCom (DXCM) Stock Is Up Today - Quiver Quantitative
Why DexCom Inc (DXCM) Is Set to Outperform the Market: Insights into Financial Growth and Competitive Advantage - GuruFocus
Truist raises DexCom stock price target to $87 on growth outlook - Investing.com
Truist Adjusts Price Target on DexCom to $87 From $80, Maintains Buy Rating - marketscreener.com
US252131AM9 Bond Profile — Key Metrics - TradingView
How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story - simplywall.st
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DXCM Company (NASDAQ: DXCM) shareholder to sell 1,700 shares - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM - Zacks Investment Research
Dexcom G7 15 Day CGM System Receives Health Canada Approval - Medical Product Outsourcing
Dexcom receives Health Canada authorization for G7 15 Day CGM By Investing.com - Investing.com South Africa
Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights - GlobeNewswire Inc.
Dexcom (DXCM) Gains Health Canada Approval for New CGM System - GuruFocus
Dexcom G7 15 Day Receives Health Canada Authorization: Extending - GuruFocus
Dexcom receives Health Canada authorization for G7 15 Day CGM - Investing.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DEXCOM,-INC. - The Facts
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes - Dexcom Investor Relations
Here's why you should retain DexCom stock in your portfolio - MSN
Dexcom stock holds steady on its glucose monitor business - Ad Hoc News
JPMorgan (NYSE: JPM) sells $2.01M DexCom-linked auto callable contingent interest notes - Stock Titan
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup - ChartMill
Is DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift? - Yahoo Finance
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom to release Q2 2026 earnings on July 30, 2026 - scanx.trade
Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems? - Sahm
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured - Yahoo Finance
Press Release: Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 P.m. Eastern Time - Moomoo
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
Dexcom Inc. focuses on continuous glucose monitoring as investors track long-term growth - AD HOC NEWS
Dexcom Inc. focuses on continuous glucose monitoring growth. Long-term diabetes trends support the b - Ad-hoc-news.de
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):